Our top pick for
Building a portfolio
Rhythm Pharmaceuticals, Inc is a biotechnology business based in the US. Rhythm Pharmaceuticals shares (RYTM) are listed on the NASDAQ and all prices are listed in US Dollars. Rhythm Pharmaceuticals employs 90 staff and has a market cap (total outstanding shares value) of USD$1.1 billion.
|52-week range||USD$15.82 - USD$43.26|
|50-day moving average||USD$24.6244|
|200-day moving average||USD$26.8161|
|Wall St. target price||USD$46.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.341|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-34.45%|
|Return on equity TTM||-59.88%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
There are currently 2.7 million Rhythm Pharmaceuticals shares held short by investors – that's known as Rhythm Pharmaceuticals's "short interest". This figure is 1.4% down from 2.7 million last month.
There are a few different ways that this level of interest in shorting Rhythm Pharmaceuticals shares can be evaluated.
Rhythm Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rhythm Pharmaceuticals shares currently shorted divided by the average quantity of Rhythm Pharmaceuticals shares traded daily (recently around 411268.59756098). Rhythm Pharmaceuticals's SIR currently stands at 6.56. In other words for every 100,000 Rhythm Pharmaceuticals shares traded daily on the market, roughly 6560 shares are currently held short.
However Rhythm Pharmaceuticals's short interest can also be evaluated against the total number of Rhythm Pharmaceuticals shares, or, against the total number of tradable Rhythm Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rhythm Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Rhythm Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.0733% of the tradable shares (for every 100,000 tradable Rhythm Pharmaceuticals shares, roughly 73 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Rhythm Pharmaceuticals.
Find out more about how you can short Rhythm Pharmaceuticals stock.
We're not expecting Rhythm Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Rhythm Pharmaceuticals's shares have ranged in value from as little as $15.82 up to $43.26. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rhythm Pharmaceuticals's is 1.4551. This would suggest that Rhythm Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Steps to owning and managing PNRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing PINC, with 24-hour and historical pricing before you buy.
Steps to owning and managing POAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTS, with 24-hour and historical pricing before you buy.
Steps to owning and managing PTMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPOP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLYA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAGP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.